- EnteroMedics (ETRM +31.4%) soars after announcing 18-month safety and efficacy results from ReCharge (pivotal VBLOC study).
- Summary: Treatment group EWL, 25% and 10% TBL; control group, 12% EWL and 4% TBL.
- Results were statistically superior at p<.0001.
- SAE rate at 18 months: 4.3% (12-month threshold was 15%).
- "These study results, along with multi-year data from our earlier clinical trials, demonstrate durability of effect and a superior record of safety," CEO Mark Knudson says. (PR)
EnteroMedics posts big gains on VBLOC data
Dec 3 2013, 11:06 ET